UK-based Stabilitech has signed a manufacturing deal with New Zealand-based BioCell for its oral, investigational Covid-19 vaccine, OraPro-COVID-19.
Stabilitech chairman Wayne Channon explained: “After a successful recent fundraising round, this signed agreement represents a crucial next step for OraPro-COVID-19.
“It brings us closer to providing a vaccine that gives both mucosal and systemic immunity to Covid-19.
This will target the virus exactly where we catch it: in the mucous membranes of the mouth, nose, throat and even the eyes.
By taking this approach, we believe OraPro-COVID-19 could prove to provide the fastest route to widespread global immunity, turning the tide on the pandemic.”